media – Page 610 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Sanofi, Regeneron’s biologic shines again in asthma trial

Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
- Source: Pharmatimes
- 1,076
- November 3, 2017
asthma Clinical Trial dupilumab
Hormone replacement therapy may be beneficial for women’s memory

"Our study suggests that estrogen treatment after menopause protects the memory that is needed for short-term cognitive tasks from the effects of stress," said Alexandra Ycaza Herrera, the study's lead author and a researcher at the USC Leonard Davis School of Gerontology.
- Source: Medicalxpress
- 545
- November 3, 2017
breast cancer hormone menopause Researches women
Four-in-one flu shot may mean lifelong protection against the flu

A vaccine combining centralized ancestral genes from four major influenza strains appears to provide broad protection against the dangerous ailment, according to new research by a team from the Nebraska Center for Virology.
- Source: Medicalxpress
- 732
- November 3, 2017
gene influenza strains Researches vaccine
GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma

In October, the European Medicines Agency (EMA) granted PRIME designation to GSK2857916 for the treatment of relapsed and refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate.
- Source: gsk
- 556
- November 3, 2017
inhibitor multiple myeloma New Approvals refractory relapsed
Australian researchers to use 3D implants for bone tumour surgery

Researchers combine 3D printing and robotic surgery with advanced manufacturing. Credit: 2017 Royal Melbourne Institute of Technology.
- Source: medicaldevice-network
- 447
- November 3, 2017
3D robotic surgery
Dicerna Could Pocket $201M in NASH R&D Deal With Boehringer Ingelheim

Dicerna Pharmaceuticals and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases. Dicerna can get up to $201 million in upfront and success-based development and commercialization milestones for an undisclosed target.
- Source: biospace
- 541
- November 3, 2017
chronic liver diseases Market Views RNAi
Bristol-Myers, J&J sink cash into a new $95M European biotech fund

A venture capital firm in the Netherlands — backed by some big names in Big Pharma — has raised $95 million in a new fund to fuel European biotech startups.
- Source: Endpts
- 616
- November 3, 2017
diagnostics funding Market Views medical device therapeutics
Cancer-detecting start-up Grail is seeking more funding, mere months after raising $900 million

Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. The company had previously raised $100 million in 2016.
- Source: Cnbc
- 461
- November 2, 2017
cancer detection funding Market Views
AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie, a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. , announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.
- Source: news.abbvie
- 736
- November 2, 2017
antagonist biopharmaceutical GnRH New Approvals
Scientists discover 27 genes that could halt cancer

From an analysis of more than 2,000 tumors spanning 12 types of human cancer, scientists have identified 27 new genes that could stop the disease in its tracks.
- Source: medicalnewstoday
- 676
- November 2, 2017
cancer Researches suppressor genes tumor

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.